Pure Global
NCT05768061

HBV Reactivation in Anti CD20 Treatment

HaEmek Medical Center, Israel·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatitis B
Study type
Observational
Sponsor & location
Primary sponsor
HaEmek Medical Center, Israel
Location
Afula, Israel
Timeline & enrollment
Phase
N/A
Start date
Dec 16, 2021
End date
Dec 01, 2023
Enrollment
5000 participants
Primary outcome

HBV DNA in the blood.

Summary

The goal of this observational study is to test and describe the frequency of hepatitis B
 virus reactivation in patients who received anti-CD20 drugs for a wide variety of autoimmune
 and hemato-oncological diseases in order to find out whether a group of patients from a
 certain field was more sensitive to treatment in this respect than patients from other
 fields.

ICD-10 classifications
Acute hepatitis BAcute hepatitis B without delta-agent and without hepatic comaAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agentChronic viral hepatitis B without delta-agent : other and unspecified phase
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05768061
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05768061 through Pure Global AI's free database. This phase not specified trial is sponsored by HaEmek Medical Center, Israel and is currently Not yet recruiting. The study focuses on Hepatitis B. Target enrollment is 5000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.